Ovarian PRP: What It Is and Why It Remains Experimental
Key Takeaways
Ovarian PRP uses a concentrate from the patient’s own blood, injected into the ovaries. It is studied for diminished ovarian reserve and poor response. Early reports describe marker changes and occasional pregnancies, but evidence certainty is low and the treatment is still experimental.
What ovarian PRP is
Ovarian PRP uses a concentrate from the patient’s own blood, injected into the ovaries. It has drawn attention among patients with diminished ovarian reserve or poor ovarian response. Interest is not the same as proof.
What it is trying to do
Researchers hope PRP may:
- influence tissue signalling inside the ovary,
- affect local blood flow,
- modify inflammatory pathways,
- support function of existing follicles in selected patients.
Those mechanisms are biologically plausible. They do not guarantee usable eggs, embryos, or live birth.
What human studies suggest so far
Some studies report changes after ovarian PRP in:
- AMH, FSH, or antral follicle count,
- oocyte retrieval numbers,
- embryo creation,
- occasional spontaneous pregnancies or live births.
Interpretation is hard because:
- many studies are small,
- preparation and injection protocols differ,
- patient selection is inconsistent,
- control groups are often weak or absent,
- live birth data are thinner than early hormone changes.
Systematic reviews may show a possible signal. They also underline low certainty.
Who asks about ovarian PRP most often
- diminished ovarian reserve,
- poor ovarian response in IVF,
- premature ovarian insufficiency,
- repeated disappointing cycles and interest in experimental options.
What matters is whether PRP changes the probability of usable eggs or a live birth compared with standard planning — not whether the idea sounds innovative.
Why it remains experimental
Still unsettled:
| Open question | Why it matters |
|---|---|
| How concentrates are prepared | Results may not be comparable across clinics |
| Dose and injection technique | Bilateral vs unilateral; volume; guidance method |
| Who benefits | Age, AMH, prior response all differ |
| How long any effect lasts | A short lab bump is not a lasting fertility fix |
| Placebo / cycle variation | Markers fluctuate without PRP |
This is why ovarian PRP should be discussed as investigational or low-certainty — not as routine fertility care.
How to weigh an ovarian PRP offer
If a clinic proposes ovarian PRP, ask for written answers before you travel or pay:
- Who is selected (AMH range, age band, prior poor response definition)?
- How is the concentrate prepared, and is the protocol published or audited?
- What outcome will be measured — hormone markers only, eggs retrieved, or live birth?
- What is the follow-up window, and what happens if markers do not move?
- How does the fee and delay compare with a standard IVF or donor-egg discussion when age is already limiting?
An experimental option can still be discussed honestly. It should not displace clearer decisions about timing, egg number expectations, or alternative paths.
Risks and practical issues
Autologous blood lowers the chance of immune rejection. The procedure is still invasive and may involve:
- pelvic discomfort,
- bleeding or infection risk,
- sedation or anesthesia depending on technique,
- cost without proven benefit,
- lost time when age already limits options.
For established paths, see how many eggs for IVF and egg freezing planning. Adjacent experimental talk: exosomes and ovarian rejuvenation.
Related reading
- Exosomes for ovarian rejuvenation: still experimental
- How many eggs are usually enough for IVF?
- Egg freezing: age and numbers
FAQ
Is ovarian PRP a standard fertility treatment?
No. Protocols, selection, and live-birth evidence are not strong enough for routine care.
What changes have studies reported after PRP?
Some report shifts in AMH, FSH, follicle count, oocytes, embryos, or pregnancies — often in small or weakly controlled studies.
What is the main risk of trying PRP?
Besides procedural risks, the practical risk is losing time and money without proven benefit — especially when age is already limiting.
Who should be especially cautious?
Patients with age-limited fertility, very low reserve, or urgent timelines should be cautious about delaying established options for an experimental step.
Sources
- PRP treatment of the ovaries in diminished ovarian reserve: systematic review and meta-analysis
- Intraovarian PRP for POI and POR: systematic review and meta-analysis
- ASRM: Fertility evaluation of infertile women (2021)
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.